Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity
Kidney360 · 2026-05 · 7 (5) · 1150-1159
DOI: 10.34067/kid.0000001194 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 19.03.2026. Verfasst von Akash Mathavan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Florida, Gainesville, Florida. Hauptthemen laut MEDLINE: Cisplatin, Sodium-Glucose Transporter 2 Inhibitors, Antineoplastic Agents, Kidney Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cisplatin remains a key chemotherapy for many solid tumors, but its dose-limiting nephrotoxicity affects up to one third of patients and has no effective pharmacologic prevention beyond hydration and magnesium supplementation. Preclinical studies highlight sodium-glucose cotransporter 2 (SGLT2) inhibitors as promising nephroprotective agents during cisplatin therapy, independent of glucose lowering. We conducted a PubMed search using predefined terms related to cisplatin nephrotoxicity and SGLT2 inhibitors, identifying seven nondiabetic rodent studies. Across these models, SGLT2 inhibitors consistently attenuated kidney injury through complementary mechanisms such as suppression of inflammatory, oxidative, and apoptotic pathways; activation of AMP-activated protein kinase–dependent autophagy; reduction of kidney platinum accumulation; and, uniquely, correction of cisplatin-induced hypomagnesemia, a clinically significant complication. Protective effects occurred without compromising cisplatin’s antitumor efficacy in vitro . Overall, these findings support SGLT2 inhibitors as a mechanistically versatile strategy that targets key injury pathways in platinum nephrotoxicity. Although prospective clinical application remains untested, the strong biologic rationale, reproducibility across models, and established safety of SGLT2 inhibitors in other populations underscore the urgency of translation. Future clinical trials should incorporate rigorous assessments of kidney function, tubular injury biomarkers, and urinary extracellular vesicle profiling to define the safety, efficacy, and mechanistic insights of SGLT2 inhibitors in cisplatin nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Florida, Gainesville, Florida.
- Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, Florida.
ORCID-Profile: Akash Mathavan, Chintan V Shah
Zitieren
APA
Mathavan, A., Mathavan, A., & Shah, C. V. (2026). Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity. Kidney360, 7(5), 1150-1159. https://doi.org/10.34067/kid.0000001194
Vancouver
Mathavan A, Mathavan A, Shah CV. Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity. Kidney360. 2026;7(5):1150-1159. doi:10.34067/kid.0000001194
BibTeX
@article{Mathavan2026,
author = {Mathavan, Akash and Mathavan, Akshay and Shah, Chintan V},
title = {Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity},
journal = {Kidney360},
year = {2026},
volume = {7},
number = {5},
pages = {1150--1159},
doi = {10.34067/kid.0000001194}
}
EUVIMED